Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer
-
Published:2024-09
Issue:9
Volume:9
Page:103694
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Xu-Vuillard A.,
Guerin-Charbonnel C.,
Bocquet F.,
Cheeseman S.,
Kubelac P.M.,
Zenatri M.,
Hall G.,
Achimas-Cadariu P.,
Hanvic B.,
Fenton H.,
Sturz-Lazăr A.-M.-L.,
Augereau P.,
Ray-Coquard I.,
Leary A.,
Frenel J.-S.ORCID
Funder
Pfizer
Clovis Oncology
Gilead Sciences
GlaxoSmithKline